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Abstract
Background—The underpinnings of the migraine-stroke association remain uncertain, but
endothelial activation is a potential mechanism. We evaluated the association of migraine and
vascular disease biomarkers in a community-based population.
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Methods—Participants (300 women, 117 men) were recruited as a part of the Dutch CAMERA 1
(Cerebral Abnormalities in Migraine, an Epidemiologic Risk Analysis) study. Participants were:
ages 30–60 (mean 48) years, 155 migraine with aura (MA), 128 migraine without aura (MO), and
134 controls with no severe headaches. Plasma concentrations of fibrinogen, Factor II, D-dimer,
high sensitivity C-reactive protein (hs-CRP), and von Willebrand factor antigen were compared
between groups, also stratifying by sex.
Results—Fibrinogen and hs-CRP were elevated in migraineurs compared to controls. In logistic
regression analyses, MO and MA had increased likelihood of elevated fibrinogen, MA had
increased likelihood of elevated Factor II and hs-CRP. Fibrinogen and Factor II were associated
with MA in women but not men. In the migraine subgroup, total number of years of aura, but not
headache, predicted elevated hs-CRP, and average number of aura, but not headache, attacks
predicted all biomarkers but Factor II.
Conclusions—Elevated vascular biomarkers were associated with migraine, particularly MA, as
well as with years of aura and number of aura attacks.
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Introduction
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Migraine is associated with stroke, particularly migraine with aura (1). The migraine
populations at highest stroke risk includes women, those with high attack frequency, and
long duration since migraine onset (1,2). Additional factors strengthening the migrainestroke relationship include the absence of many of the conventional cardiovascular risk
factors for atherosclerotic disease (3). In the context of these epidemiological findings, the
mechanisms to account for the migraine-stroke association have been of considerable
interest. There is likely a link to an increased (e.g. genetic) propensity to develop cortical
spreading depression (the electrophysiological correlate of migraine aura), as reported in
FHM1-mice (4). Further, numerous studies suggested that there might be increased
endothelial activation in migraine, characterized by a pro-coagulatory and pro-inflammatory
milieu, but results were variable (5). A clinic-based case-control study of premenopausal
women reported a robust relationship between biomarkers of oxidative stress, coagulation,
and inflammation (6) in interictal ICHD 2-defined migraine (7). The migraine-biomarker
association was influenced by migraine frequency and subtype, being stronger for migraine
with aura (MA) than for migraine without aura (MO). To date, most of the studies on
biomarkers in migraine have been limited by the size, age, sex of the populations, or by the
methods of migraine ascertainment.
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Our objective in this study was to overcome such limitations, and to determine, within a
well-characterized community-based population of men and women across the spectrum of
adulthood, whether plasma biomarkers related to endothelial activation and vascular disease
are associated with migraine. To this end, we have evaluated biomarkers from participants in
the Dutch CAMERA 1 (Cerebral Abnormalities in Migraine, an Epidemiologic Risk
Analysis) study (8). In this population we were able to examine the influence of the strokeassociated clinical phenotype (including MA, female sex, and long duration and high attack
frequency of aura and of headache) on the relationship of vascular disease biomarkers and
migraine.

Methods
Participants and Sample Selection

Author Manuscript

The Dutch general population-based Genetic Epidemiology of Migraine (GEM) and its
substudy, the CAMERA 1 Study have been described previously (8). In brief, 863 persons
with migraine, diagnosed according to the ICHD 2 criteria (7), and 5628 controls were
identified in the GEM study (9). Controls were people who indicated that they had no severe
headaches that interfered with their daily activities. This excluded people with chronic daily
headache and cluster headache, but people with possible mild migraine attacks or episodic
tension-type headache may have been included. From those between the ages of 30 to 60
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years, 134 MO, 161 MA, and 140 controls, who were frequency matched by sex, five-year
age strata, and place of residence, were randomly selected for the MRI and vascular
biomarker study. Cases and controls did not differ by age, sex, and cardiovascular risk
factors (including low education, body mass index [BMI], hypertension, cholesterol,
diabetes, smoking, and alcohol use). The CAMERA 1 protocol included a structured
telephone interview and a clinic visit for a brain MRI, blood draw, and a standard physical
and neurological examination (8). To help the participants estimate headache and aura attack
frequency, the interview was structured to allow persons to recount their history of migraine
using their own benchmarks for when a different pattern started and stopped. In addition to
reported age at first and last migraine and aura attack, these data were used to calculate a
weighted average of the number of attacks per month. All participants gave written informed
consent and participated without any financial reimbursement. The study protocol was
approved by the Leiden University Medical Center, Netherlands ethics committee, and
exempt from the University of Toledo, USA Institutional Review Board.
Measurement of Confounders and Covariates
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Sociodemographic and medical characteristics were assessed by interview. Education was
categorized into low (primary school or lower vocational education) and high. Smoking
history was defined as never, former, and current and, for ever smokers, pack-years of
exposure. The average alcohol intake in the past year was based on responses to questions on
frequency and quantity of drinks per occasion and categorized into none, moderate (1–3
drinks per day), and high (≥3 drinks per day). Women reported the number of years they
used oral contraceptives (OC). Measured weight and height were used to calculate body
mass index (BMI: weight in kilograms divided by the square of height in meters). Blood
pressure (BP) was the mean of 3 measurements obtained at 1- minute intervals in the upper
arm with an electronic oscillometric BP monitor. Hypertension was defined as a systolic BP
of 160 mmHg and higher or a diastolic BP of 95 mmHg and higher or current use of
antihypertensive drugs. A measure of total cholesterol was available from the baseline GEM
examination (8).
Laboratory Testing
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The samples were collected ≥ 3 days after and >3 day before a migraine attack during 1999
and 2000. Samples were taken in a non-fasting state from an ante-cubital vein, labeled,
processed within one hour after venipuncture, and frozen at −70 degree Celsius. Assays
were performed in the University of Toledo Laboratory Services blinded to the participants’
health and laboratory information. Von Willebrand factor (vWF) antigen (Ag), a wellestablished plasma marker of endothelial activation and dysfunction, was analyzed by
immuno-turbidimetric method, using 0.5 ml of plasma using an automated instrument (STAR Evolution® (Diagnostica Stago) (10), with limits of detection being 3%–420%. High
sensitivity C-reactive protein (hs-CRP) was measured by Near Infrared Particle
Immunoassay rate methodology using 0.5 ml serum using instrument IMMAGE®
Immunochemistry Systems (Beckman Coulter) (11), with limits of detection being 0.2
mg/L- 1440 mg/L. Fibrinogen was analyzed by clot based method using 0.5 ml of plasma
analyzed by STA-R Evolution® (Diagnostica-Stago) (12), with limits of detection being 60
mg/dL – 1800 mg/dL. D-dimer is measured by immuno-turbidimetric method using 0.5 ml
Cephalalgia. Author manuscript; available in PMC 2019 March 01.
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of Plasma analyzed by STA-R Evolution® (Diagnostica-Stago) (13), with limits of detection
being 0.27mcg/mL FEU – 20.0 mcg/mL FEU. Factor II activity is measured by mechanical
clot methodology, an automated method using 0.5 ml plasma analyzed by STA-R
Evolution® (Diagnostica-Stago) (14), with limits of detection being 2%–1200%.
Statistical Analysis
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Based on previous studies of migraine and stroke, and of migraine and biomarkers, the focus
of our analysis was primarily on the association of biomarker levels with migraine, and its
subtypes, MA and MO. Initially the relationship was examined at the cohort level, then
repeated after stratifying by sex. The analysis was extended to explore the biomarker
association with migraine variables such as headache attack frequency and duration since
onset of headache. Within the MA cohort, we assessed biomarker association with aura
frequency and duration since onset of aura. Data were analyzed using the Statistics Package
for Social Sciences (SPSS) version 21.0. Level of significance was set a priori at p < 0.05 to
reduce the type I error rate. Descriptive statistics were reported as means and standard
deviations for continuous and frequencies and percentages for categorical variables. The
differences in mean vascular biomarker levels between migraine and control groups were
obtained by computing independent samples t- tests. For a secondary approach, biomarkers
were divided based on population medians, and values corresponding to greater than or
lower than the median values, were used to define elevated or lower levels of biomarkers for
all study participants. Risk of having elevated levels of biomarkers was derived by
computing the odds ratios with logistic regression analyses. Adjustments for demographic
and cardiovascular risk factor variables (BMI, smoking, hypertension, cholesterol, use of
oral contraceptives) were included in the estimation of risk for elevated biomarker levels.
Odds ratios were computed through logistic regression analysis and used to examine the
association of elevated biomarkers with migraine and migraine type (MA, MO) compared
with controls. The adjusted regression model fits were verified using Hosmer Lemeshow
test. All models except that involved stratified analysis had permissible number of terms not
exceeding 10% of the sample size of the smaller group in the model. In the migraine cohort
the relationship between different biomarkers and average headache frequency, average aura
frequency, total number of years since headache onset and since aura onset was examined
using multivariate linear regression analyses. For data with deviations from normality, log
transformation was performed.

Author Manuscript
Results
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The characteristics of the study participants have been previously published (8). In brief,
patients with migraine with aura and without aura were randomly selected from the GEM
cases aged 30 to 60 years. The control group was randomly selected from the cohort to
frequency match the cases by sex, municipality, and age (Table 1). Blood samples for 18
subjects were not available (due to failed venipuncture in five, insufficient plasma in six,
hemolysis during initial processing of plasma in one, and damage to sample during transport
in six), leaving 155 subjects with MA, 128 with MO, and 134 controls. Over 70% of the
participants were women and the mean age was 48 years. There were no significant
differences across the groups in education, BMI, hypertension, diabetes mellitus, tobacco
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use, serum cholesterol, and alcohol consumption. In a comparison of the women in the
control and migraine groups, there was no difference between the proportions of long
duration (>15 years) contraceptive use (24.0% v. 24.4%, p=0.94). There were no differences
between the frequency of migraine in days per year within the MA and MO subtypes.
The biomarkers we selected are related to vascular disease. With the exception of the pairing
of d-dimer and factor II, there were significant positive correlations between each biomarker
pairing (data not shown). Adjusting for age, the strongest correlations were between
fibrinogen and hs-CRP (0.547, p<.001), fibrinogen and factor II (0.356, p<.001), and hsCRP and factor II (0.307, p<0.001). In the controls these three correlations, but no others,
were significant. In the migraine group, and in the MA subgroup, all biomarker correlations
were significant, except for between D-dimer and each of the following: factor II, vWF Ag,
and fibrinogen.

Author Manuscript

In the primary approach, we examined the mean levels of biomarkers between control and
migraine groups (all migraine, MA and MO) (Table 1). Levels of fibrinogen and hs-CRP
were elevated in those with migraine as compared to controls, and levels of fibrinogen were
elevated in the MA subgroup compared to controls. Biomarker levels did not significantly
differ between MA and MO. Adjustment for age, sex, and level of education did not alter the
results.

Author Manuscript

In the secondary approach, we made an unadjusted comparison between control and
migraine, MA and MO groups based on the proportion of persons with biomarker levels
above the population median. We demonstrated that compared to controls elevated levels of
fibrinogen, factor II and hs-CRP were more likely to occur in those with migraine and with
MA, and elevated levels of fibrinogen in those with MO (Table 2, Model 1). When adjusted
for factors predictive of some or all of the examined biomarkers (age, sex, BMI, smoking
status, hypertension, and cholesterol), elevated OR remained for fibrinogen in the migraine
group and in the MA and MO subgroups and for Factor II in the migraine group and in the
MA subgroup (Table 2, Model 2). For hs-CRP the association with migraine and with MA
did not remain significant.
When stratifying by sex, and controlling for age, BMI, smoking status, hypertension,
cholesterol, and OC use (>15 years), we found in women that elevated levels of fibrinogen
and factor II were more likely in the migraine group and in the MA subgroup compared to
controls (Table 3). By contrast, in men vascular biomarkers were not associated with
migraine and with MA (Table 3).

Author Manuscript

In the migraine group we assessed the relationship between biomarkers with total years
since onset and attack frequency for both headache (in MA and MO) and aura (in MA) by
conducting a multivariate linear regression. Headache and aura frequencies were log
transformed and age, gender, BMI, and smoking status were included as covariates. Total
number of years of headache attacks and average number of headache attacks were not
associated with biomarkers. However, total number of years of aura attacks was a significant
predictor of hs-CRP (β=0.32, p<0.001). In addition, the average number of aura attacks was
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a significant predictor of hs-CRP (β=0.39, p<0.001), vWF Ag (β=0.22, p=0.007), D-dimer
(β=0.26, p=0.001), and fibrinogen (β=0.16, p=0.036).

Discussion
Our results show that in a population-based cohort selected vascular disease biomarkers are
elevated in migraine, particularly in the subgroups most strongly linked to ischemic stroke
risk– those with aura, and women. We also demonstrated that within the MA subgroup, it
was aura, not headache, attack frequency and duration since onset that strengthened the
association with the biomarkers of fibrinogen, hs-CRP, vWF Ag, and D-dimer.

Author Manuscript
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The major strengths of this study include its population-based design, a standardized
diagnosis of migraine following ICHD 2 criteria,7 and the detailed description of the cohort
that allowed us to control for possibly confounding factors due to other cardiovascular
diseases. All specimens were collected within one year and randomly relative to migraine
status. Limitations include the fact that the blood samples were analyzed nearly a decade
after collection. The lower values in this study of the biomarkers fibrinogen and hs-CRP
compared to some other studies (5,15) indicate that the samples may have lost some of their
biological activity. It is however unlikely that there was any differential loss between the
migraine and control samples, leading to false associations. Another limitation is the
possibility of unaccounted factors influencing the biomarkers, such as the effect of insulin
and glucose on fibrinogen. Our samples were non-fasting, although with examinations of
both cases and controls equally distributed over the day, a “fasting” effect in one or the other
group is unlikely. The small sample size may have resulted in lack of power to detect
associations between migraine and biomarkers that may potentially exist in larger samples,
and also to evaluate potential differences in subgroups, such as pre-and postmenopausal
woman. Given the cross-sectional nature of the study, cause and effect relationships cannot
be established for the association between migraine, and elevated biomarkers. This study
also includes exploratory analyses and adjustment of p-values for multiple hypotheses
testing was not performed and certain findings may be due to chance.
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Novel discoveries from this study are the finding that elevated fibrinogen and Factor II levels
were closely associated with migraine, particularly in women with MA. These associations
were robust even when controlling for traditional stroke risk factors. Fibrinogen is involved
in primary hemostasis, platelet aggregation, and leukocyte– endothelial cell interaction, and
it is the major determinant of whole blood and plasma viscosity (16). Inflammation, from
any cause, triggers hepatic fibrinogen production. Elevated fibrinogen levels, in turn, induce
a state of hypercoagulability, cause inflammation and endothelial injury, and aggravate
cerebral hypoperfusion (17). Fibrinogen may also damage blood vessel walls by causing
smooth muscle proliferation and migration (18). Thus, elevated fibrinogen may be either the
cause or consequence of endothelial injury. In some, but not all, epidemiological studies
fibrinogen has been linked to heart disease and stroke, including in young and middle-aged
adults (19). Plasma fibrinogen levels have also been associated with the risk of silent
cerebrovascular lesions (20). A recent systematic review revealed only a few studies of
fibrinogen in migraine (5). One small study reported an increase of plasma fibrinogen in
migraineurs compared to controls (21), whereas another small study reported slightly lower
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plasma levels in persons with migraine (22). The large Women’s Health Study, which
included women >45 years of age, found no differences in fibrinogen levels between
migraine and control groups (16).
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Coagulation factor II, also known as plasma prothrombin, is a vitamin K– dependent proenzyme that functions in the blood coagulation cascade and is required in the formation of
fibrin. Increased levels of factor II, as occurs with the inherited prothrombin G20210a
mutation, has been associated with 2 to 3 fold increased risk for the development of
thrombosis, but usually in the venous system (23). The mutation has been associated with
cryptogenic stroke, hypothesized to be related to paradoxical embolism with patent foramen
ovale (24). Studies of the prothrombin G20210a mutation in migraine revealed no difference
in the prevalence in persons with migraine compared to controls, including in migraineurs
who have coexisting ischemic cerebrovascular disease (25). In our study, coagulation factor
II was associated with migraine, especially migraine with aura, but unlike all the other
markers, in linear regression analysis factor II was not associated with aura frequency or
duration since aura onset in the MA subgroup.

Author Manuscript

We found that hs-CRP, a marker of inflammation and vascular disease, was elevated in
migraine. The association of hs-CRP with migraine had been previously demonstrated in
four case-control studies (6,26–28), including one with MO (26) and two with MA (6,27).
Large population-based studies have also demonstrated that hs-CRP is elevated in persons
with headache in children and adolescents (29) and in older individuals (15). In the
population-based Reykjavik Study, however, hs-CRP levels were not increased among
migraine sufferers compared with non-migraineurs (30). In analysis of the subgroup of
young adult women (19–34 years), those with MO had borderline higher hs-CRP levels than
non-migraineurs and those with MA (1.01mg/l vs. 0.81 and 0.75mg/l, p=0.08 and p=0.08).
Plasma levels of vWF antigen, a well-established marker of endothelial activation, correlated
positively with all the other biomarkers, as well as with aura frequency and duration since
onset in the MA cohort. Von Willebrand factor antigen levels were not, however, elevated in
migraine compared to controls. This is in contrast to our clinic-based study where
premenopausal women with migraine had higher adjusted odds ratios for elevated von
Willebrand factor activity (OR 6.51; 95% CI, 1.94 to 21.83) (6). There are substantial
differences in the populations of these two studies, including population type (clinic vs.
general), proportion of females (100% vs. <75%), mean age (38 years vs. 48 years) and
headache frequency (12 days per month vs. 1.4 days per month). Further study is needed to
clarify the reasons for the discrepant results.
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Conclusions
This study suggests that endothelial activation, as manifested by elevated biomarkers of
hypercoagulability and inflammation, is associated with migraine, particularly in women.
The correlation of biomarker levels with aura frequency and total number of aura-years
suggests the possibility that aura is causally related to endothelial activation. If true,
treatments that prevent aura, protect and repair the vasculature, or inhibit platelet
aggregation and inflammation might prevent stroke in this at-risk subgroup of migraineurs.
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Whether elevated levels of these biomarkers are associated with subclinical MRI findings or
with increased prevalence of PFO in this population remains to be determined.
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Clinical implications
•

Case-control population-based data in a well-characterized sample
demonstrate that migraine is associated with biomarkers of hypercoagulability
and inflammation, two components of endothelial activation.

•

The presence of aura, as well as its frequency and years since onset, predict
vascular biomarker levels, which may contribute to the link between migraine
with aura and stroke.

•

Treatments that prevent aura, protect and repair the vasculature, or decrease
coagulation and inflammation may prevent stroke in this subgroup of
migraineurs.
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Levels of unadjusted biomarkers for migraine compared to controls and migraine with aura compared to
migraine without aura
Control
n=134

Migraine
n=283

Migraine with aura
n=155

Migraine without
aura n=128

48.18 (0.66)

48.52 (0.46)

48.17 (0.64)

48.95 (0.69)

Females, N (%)

94 (70)

206 (73)

111 (72)

95 (74)

Low Education, N (%)

67 (50)

145 (51)

82 (53)

63 (49)

24.41 (0.32)

25.23 (0.25)

25.56 (0.37)

24.84 (0.35)

44 (33)

115 (41)

64 (41)

51 (40)

5 (4)

4 (1)

1 (0.5)

3 (2.3)

5.23 (0.08)

5.35 (0.05)

5.36 (0.07)

5.34 (0.08)

50 (37)
94 (70)

87 (31)
183 (65)

46 (30)
102 (66)

41 (32)
81 (63)

Age, mean (SE) years

Body Mass Index, mean (SE)
Hypertension, N (%)
Diabetes Mellitus, N (%)
Total Cholesterol, mean (SE), mmol/L
Smoking

Author Manuscript

Current, N (%)
Ever, N (%)

21 (16)

21 (7)

14 (9)

7 (6)

–

16.33(1.05)

15.96(1.54)

16.77(1.39)

298.87(5.18)

316.12(3.63)¶

318(4.95) ¶

313.70(5.34)

0.35(0.02)

0.32(0.01)

0.33(0.02)

0.32(0.01)

Factor II activity, mean (SE) % lab norm

108.14(1.23)

110.21(0.96)

111.07(1.29)

109.17(1.45)

vWF antigen, mean (SE) % lab norm

109.51(1.97)

109.69(2.32)

106.55(3.05)

113.48(3.54)

2.56(0.28)

3.43(0.27) ¶

3.52(0.38)

3.30(0.39)

High (≥ 3 units/day) Alcohol Consumption, N (%)
Migraine frequency, mean (SE) days/yr
Fibrinogen, mean (SE) mg/dL
D-dimer, mean (SE) mcg/mL FEU

hs-CRP, mean (SE) mg/L

Values reported in the table are means ± standard error (SE) of biomarker levels. vWF: von Willebrand factor, hs-CRP: high sensitivity C-reactive
protein. Blood samples available for 134 controls and 283 migraineurs (Migraine with aura [MA]=155 and Migraine without aura [MO]=128)
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¶
= migraine vs. controls, p <0.05. Fibrinogen: Migraine vs. control, p=0.007, MA vs. control, p=0.02; hs-CRP: Migraine vs. control, p=0.03
Adjustment for age, gender, and education did not alter the comparison results between MA, MO, and controls.
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1

1

1

1

D-dimer

Factor II

vWF Ag

hs-CRP

0.69 (0.43–1.10)
1.74 (1.09–2.78)
p=0 02

1.60 (1.08–2.42)
p=0.02

2.03 (1.26–3.25)
p=0.003

1.76 (1.15–2.68)
p=0.008
0.77 (0.51–1.16)

1.22 (0.70–1.78)

1.03 (0.68–1.55)

OR (95% CI)
1.97 (1.23–3.16)
p=0.005

OR (95%CI)

Migraine with aura

1.88 (1.24–2.87)
p=0.003

Migraine

1.43 (0.88–2.34)

0.86 (0.53–1.39)

1.48 (0.90–2.42)

0.91 (0.56–1.49)

1.79 (1.09–2.92)
p=0.02

OR (95% CI)

Migraine without aura

Model 2 is adjusted for age + gender + BMI + smoking status + hypertension + cholesterol

Model 1 is unadjusted

1

Ref

Control

Fibrinogen

Markers

Model 1: unadjusted

1.47 (0.94–2.28)

0.69 (0.45–1.07)

1.63 (1.08–2.53)
p=0.02

0.96 (0.63–1.46)

1.76 (1.13–2.73)
p=0.01

AOR (95%CI)

Migraine

1 60 (0.97–2.64)
p=0.07

0.62 (0.38–1.01)

1.86 (1.14–3.05)
p=0.01

1.07 (0.67–1.73)

1.92 (1.16–3.19)
p=0.01

AOR (95% CI)

Migraine with aura

Model 2: adjusted

1.35(0.80–2.27)

0.78(0.47–1.29)

1.41(0.84–2.36)

0.85(0.51–1.40)

1.78(1.05–3.00)
p=0.03

AOR (95% CI)

Migraine without aura

Unadjusted and adjusted logistic regression analyses for biomarkers in migraineurs compared to controls (median split)
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1

1

1

1

1

D-dimer

Factor II

vWF Ag

hs-CRP

1.27 (0.75–2.13)

1.50 (0.81–2.80)

0.61 (0.34–1.08)

2.00 (1.11–3.64)
p=0.02

1.87 (1.08–3.09)
p=0.02
0.72 (0.43–1.21)

1.05 (0.60–1.83)

0.87 (0.53–1.42)

AOR (95% CI)
2.26 (1.24–4.13)
p=0.008

AOR (95% CI)
1.84 (1.12–3.17)
p=0.02

Ref

Migraine with Aura
n=111

Migraine
n=206

Control
n=94

Fibrinogen

Markers

1.03 (0.55–1.94)

0.86 (0.48–1.56)

1.66 (0 90–3.07)

0.70 (0.40–1.25)

1.61 (0.87–2.98)

AOR (95% CI)

Migraine without Aura
n=95

Females
Adjusted for age + BMI+ smoking+ hypertension + cholesterol + OCP

1

1

1

1

1

Ref

Control
n=40

2.03 (0.84–4.90)

0.64 (0.28–1.47)

1.30 (0.56–3.01)

1.18 (0.48–2.93)

1.49 (0.63–3.51)

AOR (95% CI)

Migraine
n=77

1.79 (0.64–4.99)

0.66 (0.26–1.68)

1.75 (0.67–4.58)

1.05 (0.38–2.93)

1.18 (0.44–3.16)

AOR (95% CI)

Migraine with Aura
n=44

3.48(1.17–10.24)
p=0.02

0.81 (0.31–2.09)

0.99 (0.36–2.70)

1.57 (0.55–4.55)

2.32 (0.83–6.50)

AOR (95% CI)

Migraine without Aura
n=33

Males
Adjusted for age + BMI+ smoking+ hypertension + cholesterol

Adjusted logistic regression analyses for biomarkers in migraineurs compared to controls (Median split)
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age

hs-CRP

vWF Ag

Factor II

D-dimer

Fibrinogen

Control Variables

0.507
0.000
414

Correlation
Significance (2-tailed)
df

414

0.000

Significance (2-tailed)
df

0.267

0.000
414

Significance (2-tailed)
df
Correlation

0.239

414

0.346

0.046

Correlation

df

Significance (2-tailed)

Correlation

.
0

df

1.000

Significance (2-tailed)

Correlation

Fibrinogen

0.000
414

0.228

414

0.000

0.231

0.683
414

−0.020

0

.

1.000

414

0.346

0.046

D-dimer

0.164
414

0.068

414

0.076

0.087

.
0

1.000

414

0.683

−0.020

414

0.000

0.239

Factor II
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Marker correlations adjusted for age (full population)

0.000
414

0.319

0

.

1.000

0.076
414

0.087

414

0.000

0.231

414

0.000

0.267

vWFAg

.
0

1.000

414

0.000

0.319

0.164
414

0.068

414

0.000

0.228

414

0.000

0.507

hs-CRP
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